FR2835749B1 - Composition pharmaceutique ameliorant le transfert de gene in vivo - Google Patents

Composition pharmaceutique ameliorant le transfert de gene in vivo

Info

Publication number
FR2835749B1
FR2835749B1 FR0201584A FR0201584A FR2835749B1 FR 2835749 B1 FR2835749 B1 FR 2835749B1 FR 0201584 A FR0201584 A FR 0201584A FR 0201584 A FR0201584 A FR 0201584A FR 2835749 B1 FR2835749 B1 FR 2835749B1
Authority
FR
France
Prior art keywords
pharmaceutical composition
gene transfer
vivo gene
composition improving
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0201584A
Other languages
English (en)
French (fr)
Other versions
FR2835749A1 (fr
Inventor
Bruno Pitard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0201584A priority Critical patent/FR2835749B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to DE60305443T priority patent/DE60305443T2/de
Priority to US10/502,973 priority patent/US7709452B2/en
Priority to EP03718854A priority patent/EP1471944B1/fr
Priority to JP2003565527A priority patent/JP4613011B2/ja
Priority to AT03718854T priority patent/ATE326986T1/de
Priority to PCT/FR2003/000407 priority patent/WO2003066104A2/fr
Priority to AU2003222896A priority patent/AU2003222896A1/en
Priority to ES03718854T priority patent/ES2265569T3/es
Priority to CA2473212A priority patent/CA2473212C/fr
Publication of FR2835749A1 publication Critical patent/FR2835749A1/fr
Application granted granted Critical
Publication of FR2835749B1 publication Critical patent/FR2835749B1/fr
Priority to US12/659,618 priority patent/US8367631B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR0201584A 2002-02-08 2002-02-08 Composition pharmaceutique ameliorant le transfert de gene in vivo Expired - Lifetime FR2835749B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0201584A FR2835749B1 (fr) 2002-02-08 2002-02-08 Composition pharmaceutique ameliorant le transfert de gene in vivo
ES03718854T ES2265569T3 (es) 2002-02-08 2003-02-07 Composicion farmaceutica que mejora la transferencia de genes in vivo.
EP03718854A EP1471944B1 (fr) 2002-02-08 2003-02-07 Composition pharmaceutique ameliorant le transfert de gene in vivo
JP2003565527A JP4613011B2 (ja) 2002-02-08 2003-02-07 ｉｎｖｉｖｏ遺伝子伝達を改善する医薬組成物
AT03718854T ATE326986T1 (de) 2002-02-08 2003-02-07 Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung
PCT/FR2003/000407 WO2003066104A2 (fr) 2002-02-08 2003-02-07 Composition pharmaceutique ameliorant le transfert de gene in vivo
DE60305443T DE60305443T2 (de) 2002-02-08 2003-02-07 Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung
US10/502,973 US7709452B2 (en) 2002-02-08 2003-02-07 Pharmaceutical composition which improves in vivo gene transfer
CA2473212A CA2473212C (fr) 2002-02-08 2003-02-07 Composition pharmaceutique ameliorant le transfert de gene in vivo
AU2003222896A AU2003222896A1 (en) 2002-02-08 2003-02-07 Pharmaceutical composition which improves in vivo gene transfer
US12/659,618 US8367631B2 (en) 2002-02-08 2010-03-15 Pharmaceutical composition which improves in vivo gene transfer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0201584A FR2835749B1 (fr) 2002-02-08 2002-02-08 Composition pharmaceutique ameliorant le transfert de gene in vivo

Publications (2)

Publication Number Publication Date
FR2835749A1 FR2835749A1 (fr) 2003-08-15
FR2835749B1 true FR2835749B1 (fr) 2006-04-14

Family

ID=27620039

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0201584A Expired - Lifetime FR2835749B1 (fr) 2002-02-08 2002-02-08 Composition pharmaceutique ameliorant le transfert de gene in vivo

Country Status (10)

Country Link
US (2) US7709452B2 (https=)
EP (1) EP1471944B1 (https=)
JP (1) JP4613011B2 (https=)
AT (1) ATE326986T1 (https=)
AU (1) AU2003222896A1 (https=)
CA (1) CA2473212C (https=)
DE (1) DE60305443T2 (https=)
ES (1) ES2265569T3 (https=)
FR (1) FR2835749B1 (https=)
WO (1) WO2003066104A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868953B1 (fr) * 2004-04-16 2006-06-30 Inst Nat Sante Rech Med Composition pour le transfert intracellulaire d'un acide nucleique.
EP2076257A4 (en) * 2006-09-15 2014-04-16 Belrose Pharma Inc POLYMER CONJUGATES WITH POSITIVELY LOADED PARTS
DE102006051623A1 (de) 2006-11-02 2008-07-31 Horn, Peter A. Verfahren und Stoffgemisch zur Verbesserung eines in vivo Genfransfers
US8790664B2 (en) 2008-09-05 2014-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Multimodular assembly useful for intracellular delivery
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
WO2013106558A1 (en) 2012-01-10 2013-07-18 Merial Limited Lipid based adjuvants for dna - plasmid vaccines
WO2013128424A1 (en) 2012-03-02 2013-09-06 Institut National De La Sante Et De La Recherche Medicale Vaccine for prophylaxis or treatment of an allergen-driven and/or a chronic airways disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US20150182620A1 (en) 2012-06-15 2015-07-02 Inserm (Institut De La Sante Et De La Recherche Medicale) Polypeptides for use in the Prophylactic Treatment of Allergic Asthma
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
JP6774878B2 (ja) * 2014-04-01 2020-10-28 アンスティチュート ナショナル デ ラ サンテ エ デ ラ レシェルシュ メディカル（アンセルム） Ｒｎａの細胞内送達のための、キャップされた及びキャップされていないｒｎａ分子およびブロックコポリマー
EP3225246A1 (en) 2016-03-31 2017-10-04 Klinikum der Universität München Synthetic compound for improving efficiency of transfection
US20210000917A1 (en) 2018-03-05 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and composition for the treatment of allergic asthma
AU2020234003B2 (en) * 2019-03-11 2026-02-12 Evaxion A/S Nucleic acid vaccination using neo-epitope encoding constructs
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
EP4704818A1 (en) 2023-03-30 2026-03-11 Vivadju Pvax14 nucleic acid in combination with all-trans retinoic acid (atra) and a checkpoint inhibitor for the treatment of cancer
EP4704856A1 (en) 2023-03-30 2026-03-11 Vivadju Pvax14 nucleic acid formulated with nano-vehicle in combination with all-trans retinoic acid (atra) for activating immune pathways
WO2025129128A1 (en) 2023-12-15 2025-06-19 Vivasor, Inc. Compositions and methods for non-viral delivery of therapeutic compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
GB9216082D0 (en) * 1992-07-28 1992-09-09 Univ Nottingham Lymphatic delivery composition
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6221959B1 (en) * 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
JP2003528024A (ja) * 1997-12-16 2003-09-24 バレンティス・インコーポレーテッド 製剤化された核酸分子の無針注入
GB9904627D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Polymer compositions for polynucleotide delivery
WO2001005913A1 (en) 1999-07-16 2001-01-25 Reatech Phosphor addition in gasification
AU6389000A (en) * 1999-07-28 2001-02-19 Valentis, Inc. Sonoporation of tumors
AU2001238485A1 (en) * 2000-02-18 2001-08-27 The Immune Response Corporation Methods and compositions for gene delivery
CA2401239A1 (en) * 2000-03-03 2001-09-13 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
WO2002061040A2 (en) * 2000-10-20 2002-08-08 Valentis, Inc. Gene delivery formulations and methods for treatment of ischemic conditions

Also Published As

Publication number Publication date
DE60305443D1 (de) 2006-06-29
AU2003222896A8 (en) 2003-09-02
CA2473212C (fr) 2013-04-23
CA2473212A1 (fr) 2003-08-14
DE60305443T2 (de) 2007-05-10
AU2003222896A1 (en) 2003-09-02
EP1471944B1 (fr) 2006-05-24
US20050152870A1 (en) 2005-07-14
US20100179212A1 (en) 2010-07-15
JP4613011B2 (ja) 2011-01-12
WO2003066104A3 (fr) 2004-03-25
ATE326986T1 (de) 2006-06-15
US8367631B2 (en) 2013-02-05
JP2005522433A (ja) 2005-07-28
FR2835749A1 (fr) 2003-08-15
ES2265569T3 (es) 2007-02-16
WO2003066104A2 (fr) 2003-08-14
US7709452B2 (en) 2010-05-04
EP1471944A2 (fr) 2004-11-03

Similar Documents

Publication Publication Date Title
FR2835749B1 (fr) Composition pharmaceutique ameliorant le transfert de gene in vivo
CA2291134A1 (en) Method for the preparation of citalopram
BR0116004A (pt) Derivados de 6-o-carbamoil cetolida de eritromicina úteis como antibacterianos
BR0014199A (pt) Derivados de bifenila como inibidores de nhe-3
BR0213802A (pt) Copolìmero útil para a preparação de géis de ácidos
WO2004044136A3 (en) Compositions comprising alternating 2’-modified nucleosides for use in gene modulation
ATE541576T2 (de) 2'-o,4'-c-methylen bicyclonukleoside
EP1185546A4 (en) HIGHLY SPECIFIC PRIMERS, EXPRESSION PROCEDURES AND "KIT"
JP2005522433A5 (https=)
TR200100609T1 (tr) Sıvı çekici formunda dengelenmiş eczacılıkla ilgili bileşik
IL152673A0 (en) Nucleotide analogues comprising a reporter moiety and a polymerase enzyme blocking moiety
AU6985300A (en) Modulators of protein tyrosine phosphatases (ptpases)
DK1661905T3 (da) Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
SE0300010D0 (sv) Novel Compounds
TR200101499T1 (tr) Azepinoindol türevleri, hazırlanmaları ve kullanımları.
AU6985200A (en) Modulators of protein tyrosine phosphatases (ptpases)
CA2349227A1 (en) Substituted 2-phenylbenzimidazoles, the production thereof and their use
WO2005113571A3 (en) Methods for the delivery of oligomeric compounds
BR0208741A (pt) Derivados de piperidina
BR0109062A (pt) Inibidores de frutose-1,6-bisfosfatase de arila
BRPI0211191B8 (pt) ensaios baseados em ácido nucléico para se diagnosticar precisamente infecção por parvovírus b19 e inciadores e marcadores para uso nesses ensaios
BG105736A (en) 2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
DK0672677T3 (da) Polyamid-oligonucleotid-derivater, deres fremstilling og anvendelse
NO20021615D0 (no) Nöytralt kationisk lipid for levering av nukleinsyre og medikament
IL172015A (en) Phosphonate grouping shaft compounds, method of preparation and use thereof for the preparation of drugs for the treatment of viral infection

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20